Boston Scientific touts high success rate, pain reduction with Precision Spectra spinal cord stim
Retrospective analysis of Boston Scientific's Precision Spectra neurostim implant shows a 94% success rate and significant pain reduction at 3 months, the company reports.
Boston Scientific (NYSE:BSX) unveiled new 3-month results on its Precision Spectra spinal cord stimulation system, saying the implant resulted in significant pain reduction at 3 months and an overall success rate of 94%.
The report came from a retrospective analysis of more than 200 patients treated at 13 centers, focusing on patients with chronic pain. Patients with pain reported a reduction from a 7.8 baseline to 3.2 on average, and those with low back pain reported a reduction from a 7.0 baseline score to 2.9 on average, according to a company statement.